The first drugs entirely conceived by artificial intelligence are expected to reach the market by the end of the decade, according to Alex Zhavoronkov, CEO of Insilico Medicine. “I would be surprised if we don’t see it over the next five to six years,” Zhavoronkov stated in a Bloomberg Television interview. Insilico Medicine has more than 40 internal programs related to AI drug discovery, and Zhavoronkov hopes to be among the first to bring such drugs to market.
The development marks a significant milestone in the integration of AI technology within the pharmaceutical industry. Zhavoronkov’s confidence stems from the progress Insilico Medicine has made in leveraging AI for drug discovery. The company is at the forefront of this technological advancement, with multiple programs underway to identify and develop new drugs using AI.
As the pharmaceutical industry continues to adopt AI technologies, the potential for accelerated drug development and improved efficacy grows. Zhavoronkov’s prediction highlights the rapid progress being made in this field and the potential for AI-generated drugs to transform healthcare in the near future.
